On May 20, 2021 Exact Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT) to harness the power of ultrasound in therapeutic amplification across multiple therapeutic areas and product classes, reported that an abstract describing the background and methodology of its Phase I study, ACTIVATE, has been released for publication at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting (Press release, Exact Therapeutics, MAY 20, 2021, View Source [SID1234580358]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ACTIVATE Study (NCT04021277) is the first in a series of clinical investigations planned of the Company’s Acoustic Cluster Therapy (ACT) platform technology for targeted therapeutic enhancement.

Abstract Title: Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study)

Oral Abstract Session: Trials in Progress, Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract: TPS3145

Lead Author: Professor Udai Banerji, NIHR Professor of Molecular Cancer Pharmacology at The Institute of Cancer Research and Honorary Consultant in Medical Oncology, The Royal Marsden NHS Foundation Trust.